Customer service procedure

"Insurer profits and excess drug costs are large in dollar terms but small relative to the size of national health expenditures. Sen. Bernie Sanders and other progressives seeking the Democratic presidential nomination are zeroing in on pharmaceutical and insurer profits, money they say would be better spent providing health care for everyone under "Medicare for All. Their idea: Health care dollars from government programs, employers and families that are going into the pockets of investors instead could be used to pay for services.

To be sure, Sanders and other Medicare for All advocates also acknowledge the need to raise taxes to pay for the plan. My view is that we are having a debate in fantasy world, said Marc Goldwein, senior policy director with the nonpartisan Committee for a Responsible Federal Budget. If people want a health care system that will not bankrupt them, "the answer is to get rid of the profiteering of the drug companies and the insurance companies and move to Medicare for All, Sanders said during the recent Democratic debates.

Service procedure

Nd in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U. Securities and Exchange Commission and available at ec.

om. ov and fizer. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary data, including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the BNT162b2 vaccine candidate and dose level for the Phase 2/3 study; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license and/or emergency use authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate's benefits outweigh its known risks and determination of the vaccine candidate's efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; manufacturing capabilities or capacity, including whether the estimated numbers of doses can be manufactured within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.

This release contains forward-looking information about Pfizer's efforts to combat, the collaboration between BioNTech and Pfizer to develop a potential vaccine, an agreement with the government of Japan to supply BNT162 and other potential agreements, the BNT162 mRNA vaccine program, and modRNA candidates BNT162b2 and BNT162b1 including qualitative assessments of available data, potential benefits, expectations for clinical trials and timing of regulatory submissions, anticipated manufacturing, supply and distribution that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December.

Advertising disclosure

You may not distribute, modify, transmit or use the content of the Site or any Content, including any and all software, tools, graphics and/or sound files, for public or commercial purposes without the express written permission of the Company.

A single authorized user is licensed under this purchase and the Company retains the right to terminate or suspend all unauthorized use until payment is made in compliance with the terms. Modification of the Company Content or use of the Company Content for any other purpose is a violation of the copyright and other proprietary rights of the Company, as well as other authors who created the materials, and may be subject to monetary damages and penalties and http://workoutware.net/moneyback-guarantee.

No Company Content may be copied, reproduced, republished, uploaded, posted, transmitted, distributed, shared with others within your firm, used for public or commercial purposes, or downloaded in any way unless written permission is expressly granted by the Company.

834d4203fe